Biosafe wearable healthcare monitor has attracted significant attention owing to their applicability to wearable electronics. However, the narrow sensing range and poor response limit the application of flexible devices for comprehensive monitoring of human health-related physiological signals (i.e. pulse diagnosis). Critical challenges remain in the development of biocompatible materials and the design of flexible bio-integrated platforms for these purposes, targeting performance approaching those of conventional wafer-based technologies and long-term operational stability. In this context, this work presents a robust and flexible MXene/polydopamine (PDA)-composite-film-based pressure sensor in a portable/wearable fashion, which establishes a unique intercalated spherical-like PDA molecules structure, thereby resulting in excellent sensing performance. The MXene/PDA-based pressure sensor has sensitivity of up to 138.8 kPa-1 in the pressure range of 0.18-6.20 kPa with fast response and recovery speed (t1<100 ms; t2<50 ms). Associated embodiment involves real-time precise measurements of a variety of health-related physiological signals, ranging from wrist pulse, to finger motions, to vocalization and to facial expressions, with high sensitivity and accuracy. Studies on human subjects establish the clinical significance of these devices for future opportunities of health monitoring and intelligent control to predict and diagnose diseases.

Cuproptosis, the current form of regulated cell death characterized by copper overload, oligomerization of lipoacylated proteins, and loss of the Fe-S cluster proteins, has been proposed to function closely with human diseases including cancer. Since the first identification in 2022, a wide range of strategies have been developed to induce cuproptosis for cancer therapy, such as small-molecule drugs and nanomaterials. Although many reviews related to cuproptosis have been reported, they remain at a basic mechanism level and a summary covering recent progress in the field of nanotechnologies in cuproptosis-based cancer therapy has not yet been presented. Therefore, it is time to fill the gap and shed light on future directions for the application of this promising tool to fight against cancer. In this minireview, we first expounded the mechanism of action of cuproptosis and emphasized the feasibility of triggering cuproptosis for cancer therapy. The recent progress of cancer treatments based on nanoparticle-induced cuproptosis was then described. Finally, the challenges and future development directions of the emerging field of cuproptosis were also discussed.